BioNanomatrix to Commercialize NanoAnalyzer Platform with Series B Financing

Nanoscale technology developer for single-molecule analysis and imaging, BioNanomatrix announces that a $23.3 Million worth Series B equity financing round has been completed.

New and existing investors join the equity financing round, led by Domain Associates. Gund Investment is the new investor and existing investors of the company are KT Venture Group, Battelle Ventures, and Innovation Valley Partners.

R. Erik Holmlin, President and CEO of BioNanomatrix, states that the funding is secured at a critical time, as the company is progressing  towards commercializing the new genome analysis system, nanoAnalyzer. He also adds that the nanoAnalyzer 1000 System was  launched on November 2010 at the American Society of Human Genetics’ annual meeting.

The nanoAnalyzer platform is simple, affordable, and works efficiently. It reduces cost and time required for whole genome analysis. These benefits will make it feasible for wide range of applications such as research in biomedical, molecular diagnostics, and personalized medicine.

Dr. Brian K. Halak, who is joining BioNanomatrix’s Board of Directors, quotes that the company has made significant advance in developing and improving the nanoAnalyzer technology. The new financing supports the genomics company to establish its presence in West Coast, so that BioNanomatrix gains additional business opportunities.


Joel Scanlon

Written by

Joel Scanlon

Joel relocated to Australia in 1995 from the United Kingdom and spent five years working in the mining industry as an exploration geotechnician. His role involved utilizing GIS mapping and CAD software. Upon transitioning to the North Coast of NSW, Australia, Joel embarked on a career as a graphic designer at a well-known consultancy firm. Subsequently, he established a successful web services business catering to companies across the eastern seaboard of Australia. It was during this time that he conceived and launched News-Medical.Net. Joel has been an integral part of AZoNetwork since its inception in 2000. Joel possesses a keen interest in exploring the boundaries of technology, comprehending its potential impact on society, and actively engaging with AI-driven solutions and advancements.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Bionano. (2019, February 12). BioNanomatrix to Commercialize NanoAnalyzer Platform with Series B Financing. AZoNano. Retrieved on July 20, 2024 from

  • MLA

    Bionano. "BioNanomatrix to Commercialize NanoAnalyzer Platform with Series B Financing". AZoNano. 20 July 2024. <>.

  • Chicago

    Bionano. "BioNanomatrix to Commercialize NanoAnalyzer Platform with Series B Financing". AZoNano. (accessed July 20, 2024).

  • Harvard

    Bionano. 2019. BioNanomatrix to Commercialize NanoAnalyzer Platform with Series B Financing. AZoNano, viewed 20 July 2024,

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.